Plasma Exchange Not Seen to Lessen Risk of Death or Kidney Failure in Severe ANCA Vasculitis Patients in Phase 3 Trial
Plasma exchange — a procedure that removes plasma from the blood and replaces it with a donor-derived substitute — does not lessen a risk of end-stage renal disease (ESRD) or death in patients with severe ANCA-associated vasculitis (AAV), data from a Phase 3 trial show. Trial findings, however, appear to…